Can ketamine be used safely in patients with seizure disorders, and what are the recommended dosing and monitoring guidelines?

Ketamine and Seizures

Ketamine can be used safely and effectively in patients with refractory status epilepticus (RSE) and super-refractory status epilepticus (SRSE), but should NOT be co-administered with theophylline or aminophylline as this combination may lower the seizure threshold. 1

Key Safety Consideration: Drug Interaction Warning

The FDA label explicitly contraindicates co-administration of ketamine with theophylline or aminophylline due to seizure threshold reduction 1. This is the primary seizure-related safety concern when considering ketamine use.

Clinical Use in Refractory Status Epilepticus

When to Use Ketamine

Ketamine is recommended as an alternative treatment for RSE after failure of benzodiazepines and second-line agents (valproate, levetiracetam, phenytoin/fosphenytoin, or phenobarbital). Recent guidelines list ketamine alongside midazolam, propofol, and barbiturates for RSE management 2.

The evidence shows:

• Seizure cessation rate: 56-64% across multiple studies 3, 4
• Effectiveness in both adults (59%) and children (50%) with no significant age-related difference 4
• 90.5% seizure cessation in prehospital benzodiazepine-refractory cases 5

Dosing Guidelines

For RSE/SRSE treatment:

• Initial bolus: 0.9-1.0 mg/kg IV (used in 78.5% of cases) 6
• Maintenance infusion: Start at 10 μg/kg/min (0.6 mg/kg/hr), titrate up to 30-50 μg/kg/min as needed 6, 7
• Minimum effective rate: No responses observed below 0.9 mg/kg/hr (15 μg/kg/min) 8
• Duration: Median 39-40 hours 6, 7

For prehospital benzodiazepine-refractory seizures:

• Intramuscular: 3.3 mg/kg average
• Intravenous/intraosseous: 2.2 mg/kg average 5

Timing Matters

Earlier initiation improves outcomes. Responders received ketamine 3.2 days after seizure onset versus 4.3 days in non-responders (mean difference -0.90 days, p<0.0001) 3. No likely responses occurred when ketamine was started ≥8 days after SE onset or after failure of ≥7 drugs 8.

Monitoring Requirements

Respiratory Monitoring

• Transient hypoxia occurs in 22% of patients 5
• Bag-valve-mask ventilation needed in 31%, supraglottic airway in 7%, intubation in 2.4% 5
• Unlike other continuous infusion anesthetics, ketamine does not suppress respiratory drive, allowing use without intubation in carefully selected patients 6
• 71.4% of non-intubated RSE patients achieved seizure control without requiring intubation 6

Cardiovascular Monitoring

• Hypotension (SBP <90 mmHg) in 31.8% of patients receiving ketamine alone 6
• Hypertension (SBP >180 mmHg) in 39.3% 6
• Ketamine increases heart rate, blood pressure, and cardiac output through sympathetic stimulation 9
• Monitor vital signs continuously; consider dose adjustment when co-administered with sympathomimetics or vasopressin 1

EEG Monitoring

Continuous EEG is essential. Ketamine reduced seizure burden by ≥50% at 24 hours in 84% of patients, with complete cessation in 43% 7. Guidelines recommend continuous or prolonged EEG for RSE management 2.

Special Populations

Pediatric Considerations

• Ketamine is safe and effective in children with similar efficacy to adults 4
• Pediatric guidelines include ketamine in algorithms for both convulsive and non-convulsive status epilepticus 10
• Warning: Prolonged use (>3 hours) in children ≤3 years may cause long-term cognitive deficits 1

Patients with Elevated Intracranial Pressure

Ketamine increases cerebrospinal fluid pressure 1. Use in a monitored setting with frequent neurologic assessments in patients with elevated ICP.

Contraindications Beyond Seizure Concerns

• Known hypersensitivity to ketamine 1
• Patients where significant blood pressure elevation would be hazardous 1
• Avoid in ischemic heart disease, cerebrovascular disease, or uncontrolled hypertension 9

Drug Interactions Requiring Caution

Benzodiazepines, opioids, or CNS depressants: Concomitant use may cause profound sedation, respiratory depression, coma, or death. Close monitoring required with dose adjustment as needed 1.

Practical Algorithm for Ketamine Use in RSE

1. Confirm benzodiazepine failure and at least one second-line agent (valproate, levetiracetam, phenytoin, or phenobarbital)
2. Verify no theophylline/aminophylline use
3. Initiate within 5 days of seizure onset for optimal response
4. Give bolus 0.9-1.0 mg/kg IV over 1 minute
5. Start infusion at 10 μg/kg/min, titrate by 10 μg/kg/min every 15 minutes to seizure suppression (max 50 μg/kg/min)
6. Monitor continuously: EEG, vital signs, respiratory status, oxygen saturation
7. Maintain infusion 24-48 hours after seizure cessation
8. Prepare for respiratory support (occurs in ~30% of cases)

Outcome Data

Mortality in RSE was 43% overall, but significantly lower (16% vs 56%, p=0.0047) when seizures were controlled within 24 hours of ketamine initiation 8. Ketamine discontinuation due to adverse events was rare (0.7%) 3.